BR112014011340A2 - métodos para a preparação de análogos de nucleotídeos antivirais - Google Patents

métodos para a preparação de análogos de nucleotídeos antivirais

Info

Publication number
BR112014011340A2
BR112014011340A2 BR112014011340A BR112014011340A BR112014011340A2 BR 112014011340 A2 BR112014011340 A2 BR 112014011340A2 BR 112014011340 A BR112014011340 A BR 112014011340A BR 112014011340 A BR112014011340 A BR 112014011340A BR 112014011340 A2 BR112014011340 A2 BR 112014011340A2
Authority
BR
Brazil
Prior art keywords
preparation
methods
nucleotide analogs
antiviral nucleotide
antiviral
Prior art date
Application number
BR112014011340A
Other languages
English (en)
Inventor
anthony martins Andrew
james roberts Benjamin
A Colby Denise
S White Nicole
William Scott Robert
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of BR112014011340A2 publication Critical patent/BR112014011340A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Abstract

resumo patente de invenção: "métodos para a preparação de análogos de nucleotídeos antivirais". a invenção refere-se a métodos para o isolamento de 9-{(r)-2-[((s){[(s)-1-(isopropoxicarbonil)etil]amino}fenoxifosfinil)metoxi] propil}adenina (composto 16): um método para a preparação, a uma elevada pureza diastereomérica, dos compostos intermediários 13 e 15: e um método para a preparação do composto intermediário 12: 9-{(r)-2-[((s)-{[(s)-1-(isopropoxicarbonil)etil]amino}fenoxifosfinil)metoxi]propil}adenina que tem propriedades antivirais.
BR112014011340A 2011-10-07 2012-10-03 métodos para a preparação de análogos de nucleotídeos antivirais BR112014011340A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161544950P 2011-10-07 2011-10-07
PCT/US2012/000441 WO2013052094A2 (en) 2011-10-07 2012-10-03 Methods for preparing anti-viral nucleotide analogs

Publications (1)

Publication Number Publication Date
BR112014011340A2 true BR112014011340A2 (pt) 2017-06-13

Family

ID=47297386

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014011340A BR112014011340A2 (pt) 2011-10-07 2012-10-03 métodos para a preparação de análogos de nucleotídeos antivirais

Country Status (25)

Country Link
US (4) US8664386B2 (pt)
EP (2) EP2764002B1 (pt)
JP (2) JP6190372B2 (pt)
KR (3) KR102033802B1 (pt)
CN (4) CN103842366B (pt)
AR (1) AR088109A1 (pt)
AU (1) AU2012319172B2 (pt)
BR (1) BR112014011340A2 (pt)
CA (2) CA3042169C (pt)
CL (1) CL2014000827A1 (pt)
CO (1) CO6940431A2 (pt)
CR (1) CR20140204A (pt)
EA (1) EA027086B1 (pt)
EC (1) ECSP14000074A (pt)
ES (2) ES2661705T3 (pt)
HK (3) HK1200834A1 (pt)
IL (1) IL231879B (pt)
MX (1) MX353064B (pt)
PE (1) PE20141160A1 (pt)
PL (1) PL3333173T3 (pt)
PT (2) PT2764002T (pt)
SI (1) SI3333173T1 (pt)
TW (4) TWI557133B (pt)
UY (1) UY34361A (pt)
WO (1) WO2013052094A2 (pt)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2744810T2 (sl) 2011-08-16 2023-11-30 Gilead Sciences, Inc. Tenofovir alafenamid hemifumarat
CN103842366B (zh) 2011-10-07 2017-06-16 吉利德科学公司 制备抗病毒核苷酸类似物的方法
CN107312039B (zh) 2012-08-30 2019-06-25 江苏豪森药业集团有限公司 一种替诺福韦前药的制备方法
WO2014195724A1 (en) * 2013-06-07 2014-12-11 Cipla Limited An efficient process for separation of diastereomers of 9-[(r)-2-[[(r,s)-[[(s)-1-(isopropoxycarbonyl)ethyl]amino]-phenoxyphosphinyl] methoxy]propyl]adenine
CN104628773B (zh) * 2013-11-06 2018-10-23 杭州和泽医药科技有限公司 (r)-9-[2-(磷酰苯酚基甲氧基)丙基]腺嘌呤的制备方法
WO2015079455A2 (en) * 2013-11-27 2015-06-04 Laurus Labs Private Limited A recycling process for preparing tenofovir alafenamide diastereomers
WO2015107451A2 (en) * 2014-01-14 2015-07-23 Mylan Laboratories Ltd. Purification of tenofovir alafenamide and its intermediates
TWI660965B (zh) 2014-01-15 2019-06-01 美商基利科學股份有限公司 泰諾福韋之固體形式
WO2015161781A1 (zh) * 2014-04-21 2015-10-29 四川海思科制药有限公司 一种核苷类似物及其中间体的制备方法
WO2015197006A1 (zh) * 2014-06-25 2015-12-30 四川海思科制药有限公司 一种取代的氨基酸硫酯类化合物、其组合物及应用
CN105399771B (zh) 2014-07-21 2020-11-24 江苏豪森药业集团有限公司 替诺福韦前药晶型及其制备方法和用途
CN105646584B (zh) * 2014-11-12 2018-09-28 四川海思科制药有限公司 替诺福韦艾拉酚胺富马酸盐晶型及其制备方法和用途
CN104817593B (zh) * 2015-04-27 2016-11-16 广州同隽医药科技有限公司 半富马酸替诺福韦艾拉酚胺关键中间体的合成工艺
PE20180687A1 (es) 2015-08-05 2018-04-23 Eisai Randd Man Co Ltd Reactivos quirales para la preparacion de oligomeros homogeneos
TWI616452B (zh) * 2015-08-26 2018-03-01 Preparation method of nucleoside analog and intermediate thereof
CN105330700A (zh) * 2015-12-17 2016-02-17 中国药科大学 富马酸替诺福韦艾拉酚胺杂质的制备方法
WO2017118928A1 (en) 2016-01-06 2017-07-13 Lupin Limited Process for the separation of diastereomers of tenofovir alafenamide
CZ2016156A3 (cs) * 2016-03-17 2017-09-27 Zentiva, K.S. Způsob přípravy diastereomerně čistého Tenofoviru Alafenamidu nebo jeho solí
CN107286190A (zh) * 2016-04-13 2017-10-24 刘沛 核苷之烃氧基苄基氨基磷酸/膦酸酯衍生物的制备及其医药用途
EP3454862A4 (en) 2016-05-10 2020-02-12 C4 Therapeutics, Inc. SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN REDUCTION
CN109562107A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的杂环降解决定子体
WO2017197046A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. C3-carbon linked glutarimide degronimers for target protein degradation
CN106565785B (zh) * 2016-11-09 2019-11-12 周雨恬 一种具有抗hbv/hiv活性的核苷氨基磷酸酯类化合物及其盐和用途
CN106946935B (zh) * 2017-04-28 2020-01-07 福建广生堂药业股份有限公司 一种非对映异构体核苷衍生物的制备方法
JP2020536100A (ja) * 2017-10-04 2020-12-10 セルジーン コーポレイション シス−４−［２−｛［（３ｓ，４ｒ）−３−フルオロキサン−４−イル］アミノ｝−８−（２，４，６−トリクロロアニリノ）−９ｈ−プリン−９−イル］−１−メチルシクロヘキサン−１−カルボキサミドの製造プロセス
CN109942632B (zh) * 2017-12-20 2021-08-31 上海博志研新药物研究有限公司 替诺福韦艾拉酚胺中间体的制备方法
CN109942633B (zh) * 2017-12-20 2021-08-31 上海新礼泰药业有限公司 替诺福韦艾拉酚胺中间体的制备方法
CN110092803A (zh) * 2018-01-31 2019-08-06 北京睿创康泰医药研究院有限公司 替诺福韦艾拉酚胺富马酸盐工艺杂质的制备及其应用
CN108409788B (zh) * 2018-03-12 2020-05-08 科兴生物制药股份有限公司 一种富马酸替诺福韦艾拉酚胺的制备方法
CN110305163A (zh) * 2018-03-27 2019-10-08 北京济美堂医药研究有限公司 替诺福韦艾拉酚胺半富马酸盐的制备方法
CN108467410B (zh) * 2018-04-09 2021-04-09 重庆三圣实业股份有限公司 一种taf中间体的制备方法及产品和应用
CN108484672A (zh) * 2018-05-23 2018-09-04 中国药科大学制药有限公司 磷丙替诺福韦的手性拆分方法
CN108822149B (zh) * 2018-06-01 2020-08-11 成都苑东生物制药股份有限公司 一种富马酸替诺福韦艾拉酚胺关键中间体的制备方法
CN110283208B (zh) * 2018-06-22 2022-07-08 南京济群医药科技股份有限公司 一种替诺福韦艾拉酚胺的手性拆分方法
CN109081853A (zh) * 2018-09-03 2018-12-25 南京正大天晴制药有限公司 一种磷丙替诺福韦有关物质的制备方法
CN111484527A (zh) * 2019-01-25 2020-08-04 上海清松制药有限公司 一种替诺福韦艾拉酚胺中间体的制备方法
CN111943981A (zh) * 2019-05-14 2020-11-17 博瑞生物医药泰兴市有限公司 一种磷丙替诺福韦的制备方法
CN112175003B (zh) * 2019-07-01 2022-02-15 上海医药工业研究院 一种苯基氢膦酸酯及其中间体的制备方法
WO2021011891A1 (en) 2019-07-18 2021-01-21 Gilead Sciences, Inc. Long-acting formulations of tenofovir alafenamide
CN112390824B (zh) * 2019-08-19 2022-07-05 鲁南制药集团股份有限公司 一种替诺福韦艾拉酚胺中间体的制备方法
CN110981911A (zh) * 2019-10-08 2020-04-10 浙江车头制药股份有限公司 一种替诺福韦艾拉酚胺的制备方法
CN111171076A (zh) * 2019-12-26 2020-05-19 合肥启旸生物科技有限公司 一种替诺福韦二聚体的制备方法
CN115605493A (zh) 2020-03-20 2023-01-13 吉利德科学公司（Us） 4′-c-取代的-2-卤代-2′-脱氧腺苷核苷的前药及其制备和使用方法
KR20210125298A (ko) 2020-04-08 2021-10-18 주식회사 파마코스텍 테노포비어 알라펜아미드 헤미타르트레이트의 신규한 제조방법
KR20230107288A (ko) 2020-11-11 2023-07-14 길리애드 사이언시즈, 인코포레이티드 gp120 CD4 결합 부위-지향 항체를 이용한 요법에 감수성인 HIV 환자를 식별하는 방법
KR20220141457A (ko) 2021-04-13 2022-10-20 경동제약 주식회사 신규 결정형의 테노포비어 알라펜아미드 말레산염 및 이를 포함하는 약제학적 조성물
TW202400172A (zh) 2022-04-06 2024-01-01 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途
TW202402280A (zh) 2022-07-01 2024-01-16 美商基利科學股份有限公司 可用於ｈｉｖ病毒感染之疾病預防性或治療性治療的治療性化合物
US20240083984A1 (en) 2022-08-26 2024-03-14 Gilead Sciences, Inc. Dosing and scheduling regimen for broadly neutralizing antibodies
WO2024076915A1 (en) 2022-10-04 2024-04-11 Gilead Sciences, Inc. 4'-thionucleoside analogues and their pharmaceutical use

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ535408A (en) * 2000-07-21 2006-09-29 Gilead Sciences Inc Method for selecting prodrugs of phosphonate nucleotide analogues
US20050239054A1 (en) * 2002-04-26 2005-10-27 Arimilli Murty N Method and compositions for identifying anti-HIV therapeutic compounds
TR201906416T4 (tr) * 2004-07-27 2019-05-21 Gilead Sciences Inc Hiv inhibitörü bileşiklerin fosfonat analogları.
US20110065631A1 (en) * 2006-03-29 2011-03-17 Gilead Sciences, Inc Process for preparation of hiv protease inhibitors
PT2038290E (pt) * 2006-07-07 2013-12-10 Gilead Sciences Inc Moduladores de receptor do tipo toll 7
CA2657821A1 (en) * 2006-07-21 2008-01-24 Gilead Sciences, Inc. Aza-peptide protease inhibitors
SG174016A1 (en) * 2006-07-24 2011-09-29 Korea Res Inst Chem Tech Hiv reverse transcriptase inhibitors
KR20100041798A (ko) * 2007-06-29 2010-04-22 한국화학연구원 신규 ｈｉｖ 역전사효소 억제제
SI2744810T2 (sl) 2011-08-16 2023-11-30 Gilead Sciences, Inc. Tenofovir alafenamid hemifumarat
CN103842366B (zh) * 2011-10-07 2017-06-16 吉利德科学公司 制备抗病毒核苷酸类似物的方法

Also Published As

Publication number Publication date
PT2764002T (pt) 2018-05-16
PT3333173T (pt) 2019-09-10
TWI689513B (zh) 2020-04-01
CN103842366B (zh) 2017-06-16
JP2017160228A (ja) 2017-09-14
US9346841B2 (en) 2016-05-24
MX353064B (es) 2017-12-19
PE20141160A1 (es) 2014-09-22
EA027086B1 (ru) 2017-06-30
HK1245798A1 (zh) 2018-08-31
KR20200090975A (ko) 2020-07-29
US20150291638A1 (en) 2015-10-15
NZ624513A (en) 2016-06-24
AR088109A1 (es) 2014-05-07
CN107266498B (zh) 2023-10-03
EP3333173B1 (en) 2019-06-26
CA3042169A1 (en) 2013-04-11
ES2746859T3 (es) 2020-03-09
HK1255222B (zh) 2020-07-17
KR102033802B1 (ko) 2019-10-17
TW202003531A (zh) 2020-01-16
CN117343101A (zh) 2024-01-05
IL231879B (en) 2019-11-28
US9029534B2 (en) 2015-05-12
CA2850466A1 (en) 2013-04-11
KR102139440B1 (ko) 2020-07-29
CO6940431A2 (es) 2014-05-09
WO2013052094A2 (en) 2013-04-11
EP2764002A2 (en) 2014-08-13
KR20190086576A (ko) 2019-07-22
UY34361A (es) 2013-05-31
HK1200834A1 (en) 2015-08-14
US20160311840A1 (en) 2016-10-27
TW201331218A (zh) 2013-08-01
WO2013052094A3 (en) 2013-06-20
ES2661705T3 (es) 2018-04-03
JP6190372B2 (ja) 2017-08-30
CA2850466C (en) 2020-07-28
CN113264959A (zh) 2021-08-17
EA201490753A1 (ru) 2014-09-30
SI3333173T1 (sl) 2019-08-30
EP3333173A1 (en) 2018-06-13
TWI709567B (zh) 2020-11-11
TW201716418A (zh) 2017-05-16
US8664386B2 (en) 2014-03-04
US20140128602A1 (en) 2014-05-08
CL2014000827A1 (es) 2014-09-05
TW201811808A (zh) 2018-04-01
AU2012319172B2 (en) 2014-06-12
CN103842366A (zh) 2014-06-04
CN107266498A (zh) 2017-10-20
CR20140204A (es) 2014-06-03
CA3042169C (en) 2021-09-07
JP2014530809A (ja) 2014-11-20
AU2012319172A1 (en) 2013-05-16
PL3333173T3 (pl) 2019-12-31
EP2764002B1 (en) 2018-02-28
MX2014003952A (es) 2014-08-01
TWI613211B (zh) 2018-02-01
ECSP14000074A (es) 2016-01-29
US9676804B2 (en) 2017-06-13
US20130090473A1 (en) 2013-04-11
KR20140090170A (ko) 2014-07-16
TWI557133B (zh) 2016-11-11

Similar Documents

Publication Publication Date Title
BR112014011340A2 (pt) métodos para a preparação de análogos de nucleotídeos antivirais
GEP201706793B (en) Substituted nucleosides, nucleotides and analogs thereof
CR20120264A (es) Compuestos
EA201590943A1 (ru) Замещенные нуклеозиды, нуклеотиды и их аналоги
MD4496C1 (ro) Analogi carba-nucleozidici 2'-substituiţi pentru tratament antiviral
PH12014501134B1 (en) 2',4'-difluoro-2'-methyl substituted nucleoside derivatives as inhibitors of hcv rna replication
AR090455A1 (es) Metodos para preparar analogos de nucleotidos sustituidos
IN2014MU00118A (pt)
MX350810B (es) Derivados de los nucleosidos sustituidos en 4 '-azido, 3 '-fluoro como inhibidores de la replicacion del rna del vhc.
EA201390142A1 (ru) 2'-фторзамещенные карбануклеозидные аналоги для противовирусного лечения
GEP20166496B (en) Substituted nucleosides, nucleotides and analogs thereof
EA201390576A1 (ru) Противовирусные соединения
UA116083C2 (uk) Похідні пурину для лікування вірусних інфекцій
GEP20227397B (en) Inhibitors of influenza viruses replication
EA201390230A1 (ru) Замещенные аналоги нуклеотидов
EA201201343A1 (ru) Производные 4-аминопиримидина и их действующее вещество как антагонисты аденозинового рецептора а
BR112013001267A2 (pt) métodos para a preparação de pró-fármacos de fosforamidato diasteromericamente puro
UY33337A (es) DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS
BR112015028452A2 (pt) agonistas do receptor somastatina subtipo 4 (sstr4)
BR112014010401A8 (pt) Inibidores do vírus da hepatite c rod-like que contêm o fragmento {2-[4-(bifenil-4-il)-1h-imidazo-2-il] pirrolidina-1-carbonilmetil}amina
UA111357C2 (uk) Аналоги епоксіейкозатриєнової кислоти, композиція на їх основі, застосування для лікування захворювань та спосіб зниження гіпертонії та нефротоксичності (варіанти)
BR112013032049A2 (pt) inibidores do vírus da hepatite c
AR082968A1 (es) Inhibidores biciclicos de notum pectinacetilesterasa y una composicion farmaceutica en base al compuesto
BR112014013972A8 (pt) inibidores de hcv nssa
CR20110524A (es) Proceso para preparar compuestos antivirales

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]